Men treated for prostate cancer after surgery now have clearer evidence that extending hormone therapy from six months to two full years alongside radiation can meaningfully reduce the chance the disease spreads. The RADICALS-HD trial, one of the largest randomized studies of its kind, found that 24 months of androgen deprivation therapy paired with postoperative radiotherapy produced a 10-year metastasis-free survival rate of 78.1 percent, compared with 71.9 percent for men who received only six months of the same treatment. The results, published in The Lancet, carry a hazard ratio of 0.773 that reached statistical significance, giving oncologists and patients a concrete number to weigh against the well-known side effects of prolonged hormone suppression.
Why the extra 18 months of hormone therapy changes the clinical calculus
For years, the question was not whether androgen deprivation therapy, or ADT, helped men receiving radiation after prostatectomy, but how long it needed to last. A separate French trial, GETUG-AFU 16, had already shown that adding six months of goserelin to salvage radiotherapy improved metastasis-free survival over 112 months of follow-up. That finding established a baseline: some ADT is better than none. RADICALS-HD then asked the harder question, whether increasing the duration from roughly half a year to two years would push outcomes further.
The answer split into two companion papers. In the arm comparing six months of ADT against no ADT at all, the trial recorded 10-year metastasis-free survival of 80.4 percent versus 79.2 percent, with a hazard ratio of 0.886 and a p-value of 0.35. That gap was not statistically significant, raising a pointed question: if six months barely moved the needle compared with radiation alone within this trial, why did 24 months succeed? One explanation lies in the biology of residual disease. Men whose cancer has already recurred biochemically after surgery may harbor micrometastatic cells that need longer suppression to be controlled. A short course may simply not last long enough to starve those cells of the androgens they depend on for growth.
Another factor is timing. Many men in RADICALS-HD received radiation before their prostate-specific antigen (PSA) climbed very high, in a so-called early-salvage setting. In that context, the absolute benefit of any hormone therapy may be modest because some patients would have done well with radiation alone. Extending ADT to 24 months could be acting as an insurance policy for those with more aggressive, but still microscopic, disease that is not obvious from standard risk features at the time of treatment.
The hypothesis that the benefit concentrates in men with the fastest-rising PSA levels, specifically those whose PSA doubling time falls below six months, is testable but not yet confirmed. Patient-level subgroup data linking PSA velocity to the 24-month survival advantage have not been released in the published reports. Expert commentary has flagged this as a priority for future analysis, because identifying which men gain the most from the extra year and a half of therapy would spare lower-risk patients from side effects they do not need.
RADICALS-HD trial design and the strength of its findings
RADICALS-HD, listed as NCT00541047 on ClinicalTrials.gov, used a three-way randomization structure that allowed investigators to compare no ADT, short-course ADT of about six months, and long-course ADT of 24 months, all layered onto postoperative radiotherapy. The trial enrolled men who had undergone radical prostatectomy and were considered at risk of recurrence because of factors such as PSA rise, positive margins, or adverse pathology. Its prespecified primary endpoint was metastasis-free survival, a measure that captures both distant spread and death from any cause, and is increasingly accepted as a surrogate for overall survival in prostate cancer.
The long-course versus short-course comparison delivered the headline result. At 10 years, 78.1 percent of men on 24 months of ADT remained free of metastasis, compared with 71.9 percent of those on six months. The hazard ratio of 0.773, with a 95 percent confidence interval of 0.612 to 0.975 and a p-value of 0.029, crossed the threshold for statistical significance. That roughly six-percentage-point absolute difference translates to about one additional man in every 16 treated avoiding detectable spread over a decade. For a disease that affects large numbers of men worldwide, the population-level impact of that margin is substantial.
The internal consistency of the data also strengthens the case for a true treatment effect. The Kaplan–Meier curves for metastasis-free survival separate early and remain apart over the follow-up period, rather than crossing or converging. Sensitivity analyses adjusting for baseline prognostic factors do not erase the benefit of longer ADT. Although overall survival data are still immature, trends favoring the 24-month group are emerging, suggesting that preventing or delaying metastasis may ultimately translate into fewer prostate cancer deaths.
The results appeared in The Lancet under DOI 10.1016/S0140-6736(24)00548-8, and the companion short-course paper was published under a separate DOI in the same journal. Peer-reviewed commentary in oncology journals has since examined the trial’s design and its practical implications for treatment decisions, often highlighting how RADICALS-HD sits alongside earlier work such as GETUG-AFU 16 and the short-course comparison within the same program.
Side effects, missing data, and the next clinical question
An extra 18 months of ADT is not a minor addition. Androgen deprivation causes hot flashes, fatigue, bone density loss, sexual dysfunction, mood changes, and metabolic shifts that can raise cardiovascular and diabetes risk. For men already coping with the physical and emotional aftermath of surgery, these side effects can weigh heavily on daily life and relationships. That burden is central to the treatment conversation, because the benefit from extended therapy, while meaningful, is not dramatic for every individual.
Full toxicity and quality-of-life tables from the 24-month arm of RADICALS-HD have not yet been published beyond summary-level descriptions. Without those granular data, clinicians are left to balance a clear metastasis-free survival signal against side-effect profiles drawn largely from other trials and routine practice. In real-world settings, adherence to a two-year course can be challenging; some men may stop early because of intolerable symptoms, effectively receiving something between the six- and 24-month strategies tested in the trial.
The absence of patient-level subgroup breakdowns is the most consequential gap. Gleason grade, surgical margin status, seminal vesicle invasion, and PSA kinetics all influence recurrence risk, and different combinations of these factors could interact with ADT duration. If, for example, the entire benefit of 24 months is concentrated in men with the highest Gleason scores or the shortest PSA doubling times, guidelines might eventually recommend long-course therapy only for that subset. Conversely, if the advantage appears broadly across risk groups, a default to two years of ADT could become standard practice for most men receiving postoperative radiotherapy.
Another unresolved issue is how newer systemic agents might fit into this landscape. The RADICALS-HD protocol predates the widespread use of next-generation androgen receptor pathway inhibitors in earlier stages of prostate cancer. Future studies may test whether adding such drugs for a shorter period could match or exceed the benefit of two years of conventional ADT, potentially allowing some patients to avoid prolonged castrate-level testosterone suppression.
For now, RADICALS-HD gives patients and clinicians a more solid foundation for shared decision-making. Men considering postoperative radiation can be told that extending hormone therapy from six months to two years reduces the risk of metastatic spread over 10 years by about six percentage points, at the cost of significantly longer exposure to side effects. Those with especially aggressive features may reasonably lean toward the longer course, while men with lower-risk profiles, significant comorbidities, or strong concerns about quality of life may choose the shorter option or, in some cases, radiation alone.
As more detailed analyses emerge, including toxicity data and risk-stratified outcomes, the field will be better positioned to tailor ADT duration to individual patients rather than applying a one-size-fits-all rule. Until then, the RADICALS-HD findings mark a pivotal step in refining postoperative treatment for prostate cancer, shifting the discussion from whether to use hormone therapy at all toward a more nuanced question: how long is long enough for each man sitting in the clinic.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
